HER4 Therapeutic Perspectives
Detailed comparisons of intriguing therapies: how they work, what the evidence shows and what could change our assessment.
A growing research library
We examine competing and complementary approaches to difficult diseases. Each dated perspective starts with the scientific problem, explains the therapies in plain language and separates demonstrated benefit from a promising hypothesis.
Latest perspective · Oncology · October 10, 2026
Why active RAS inhibition and personalized mRNA vaccination represent distinct advances—and why their clinical results cannot be compared as if they treated the same patients.
Read the pancreatic cancer perspective →How we evaluate a therapy
What problem does the therapy address, and why should its mechanism matter?
Who was treated, what was the comparator and which outcomes actually improved?
Where could the approach fit, what limits it and which next result would change the assessment?
Dated archive
Each issue retains its evidence cutoff. Later perspectives can return to an earlier thesis and explain what held up, what failed and what remains unresolved.
Pancreatic cancer: Blocking its growth. Teaching the immune system to find it.Issue 01 · Daraxonrasib & autogene cevumeran · OncologyLooking for our market analysis? Read Market Perspectives →
Independent perspective. Institutional discipline. Clear recommendations.